“…We applied the BBN model to transgenic URO-Ova mice expressing a model antigen from the urothelium to follow tumor-specific T cell responses during immunotherapy 148 . We found that tumorspecific T cells infiltrated the bladder more robustly in male tumor-bearing mice treated with BCG and PD-L1 immunotherapies compared to female tumor-bearing mice, which may be one reason why men have better bladder cancer outcomes than women 148 . Importantly, however, whether this difference is mediated by sex hormones, sex chromosomes, or another mechanism is unclear and would require preclinical studies modulating each of these factors before one could conclude that AR antagonism is a viable treatment approach.…”